Acute Heart Failure—Basic Pathomechanism and New Drug Targets View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-11

AUTHORS

Heinz Rupp, Thomas P. Rupp, Peter Alter, Bernhard Maisch

ABSTRACT

In view of the high incidence of heart failure and sudden cardiac death, efforts in the development of compounds which target-specific mechanisms such as a reduced expression of SERCA2, the Ca2+ pump of sarcoplasmic reticulum, of hypertrophied cardiomyocytes of pressure-overloaded or infarcted hearts should be strengthened. Lead compounds for correcting a dysregulated gene expression are the carnitine palmitoyltransferase-1 (CPT-1) inhibitors etomoxir and oxfenicine. Since bypassing the CPT-1 inhibition by a medium-chain fatty acid diet had a lesser effect on myosin V1 proportion than on lipid droplet number, one has to infer also other mechanisms such as PPARalpha activation (FOXIB/PPARalpha). In view of the intricate interrelationship between depressed pump function and malignant arrhythmias, stimulation of endogenous antiarrhythmogenic mechanisms linked to an enhanced production of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) could potentially provide alternatives to the administration of 1 g EPA and DHA ethyl esters (minimum 84% EPA + DHA) for secondary prevention of myocardial infarction. The apparently greater efficacy of omega-3 fatty acids in post-myocardial infarction patients (GISSI-Prevention study) compared with ICD patients (SOFA study) can be attributed to the greater ischemia-induced release of membrane-bound EPA and DHA and a better compliance (one vs. four capsules daily). More... »

PAGES

727-735

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00059-006-2911-x

DOI

http://dx.doi.org/10.1007/s00059-006-2911-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1033395163

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17149674


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Arrhythmia Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiac Output, Low", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiotonic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Delivery Systems", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fatty Acids, Omega-3", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Philipp University of Marburg", 
          "id": "https://www.grid.ac/institutes/grid.10253.35", 
          "name": [
            "Molecular Cardiology Laboratory, Department of Internal Medicine and Cardiology, Philipps University of Marburg, 35043, Marburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rupp", 
        "givenName": "Heinz", 
        "id": "sg:person.01177445163.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177445163.00"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Rupp", 
        "givenName": "Thomas P.", 
        "id": "sg:person.0611545536.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611545536.24"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Alter", 
        "givenName": "Peter", 
        "id": "sg:person.01065373312.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065373312.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Philipp University of Marburg", 
          "id": "https://www.grid.ac/institutes/grid.10253.35", 
          "name": [
            "Department of Internal Medicine and Cardiology, Philipps University of Marburg, Marburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maisch", 
        "givenName": "Bernhard", 
        "id": "sg:person.0630132362.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630132362.75"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2006-11", 
    "datePublishedReg": "2006-11-01", 
    "description": "In view of the high incidence of heart failure and sudden cardiac death, efforts in the development of compounds which target-specific mechanisms such as a reduced expression of SERCA2, the Ca2+ pump of sarcoplasmic reticulum, of hypertrophied cardiomyocytes of pressure-overloaded or infarcted hearts should be strengthened. Lead compounds for correcting a dysregulated gene expression are the carnitine palmitoyltransferase-1 (CPT-1) inhibitors etomoxir and oxfenicine. Since bypassing the CPT-1 inhibition by a medium-chain fatty acid diet had a lesser effect on myosin V1 proportion than on lipid droplet number, one has to infer also other mechanisms such as PPARalpha activation (FOXIB/PPARalpha). In view of the intricate interrelationship between depressed pump function and malignant arrhythmias, stimulation of endogenous antiarrhythmogenic mechanisms linked to an enhanced production of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) could potentially provide alternatives to the administration of 1 g EPA and DHA ethyl esters (minimum 84% EPA + DHA) for secondary prevention of myocardial infarction. The apparently greater efficacy of omega-3 fatty acids in post-myocardial infarction patients (GISSI-Prevention study) compared with ICD patients (SOFA study) can be attributed to the greater ischemia-induced release of membrane-bound EPA and DHA and a better compliance (one vs. four capsules daily).", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00059-006-2911-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1087175", 
        "issn": [
          "0340-9937", 
          "1615-6692"
        ], 
        "name": "Herz", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "name": "Acute Heart Failure\u2014Basic Pathomechanism and New Drug Targets", 
    "pagination": "727-735", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9f166e073751533280231557f922ce9d30cfa2a6e3f9543b9591856e18f776d9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17149674"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7801231"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00059-006-2911-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1033395163"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00059-006-2911-x", 
      "https://app.dimensions.ai/details/publication/pub.1033395163"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000482.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s00059-006-2911-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00059-006-2911-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00059-006-2911-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00059-006-2911-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00059-006-2911-x'


 

This table displays all metadata directly associated to this object as RDF triples.

121 TRIPLES      20 PREDICATES      37 URIs      29 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00059-006-2911-x schema:about N11316d5039a14717b09ab93acbd60a5f
2 N3c11646b87c040189726559d34bf5ab3
3 N6a14633b592248ccaac175a82a5a0a0e
4 N80c0a91bd73f4a54ac5a2d941025379f
5 N82ce9d294e52428ba49314743e8952e1
6 Nbfd218989e04444e87682288581bb4c8
7 Ncd12aef9c90549eda9e2047b339df5ab
8 Nfaecdf110e8944be80b1a312f486793b
9 anzsrc-for:11
10 anzsrc-for:1102
11 schema:author N916ba933e3854317a2a8c77d4a15f6f6
12 schema:datePublished 2006-11
13 schema:datePublishedReg 2006-11-01
14 schema:description In view of the high incidence of heart failure and sudden cardiac death, efforts in the development of compounds which target-specific mechanisms such as a reduced expression of SERCA2, the Ca2+ pump of sarcoplasmic reticulum, of hypertrophied cardiomyocytes of pressure-overloaded or infarcted hearts should be strengthened. Lead compounds for correcting a dysregulated gene expression are the carnitine palmitoyltransferase-1 (CPT-1) inhibitors etomoxir and oxfenicine. Since bypassing the CPT-1 inhibition by a medium-chain fatty acid diet had a lesser effect on myosin V1 proportion than on lipid droplet number, one has to infer also other mechanisms such as PPARalpha activation (FOXIB/PPARalpha). In view of the intricate interrelationship between depressed pump function and malignant arrhythmias, stimulation of endogenous antiarrhythmogenic mechanisms linked to an enhanced production of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) could potentially provide alternatives to the administration of 1 g EPA and DHA ethyl esters (minimum 84% EPA + DHA) for secondary prevention of myocardial infarction. The apparently greater efficacy of omega-3 fatty acids in post-myocardial infarction patients (GISSI-Prevention study) compared with ICD patients (SOFA study) can be attributed to the greater ischemia-induced release of membrane-bound EPA and DHA and a better compliance (one vs. four capsules daily).
15 schema:genre research_article
16 schema:inLanguage en
17 schema:isAccessibleForFree false
18 schema:isPartOf N43cce8e2643240e1ab45e2af64841e82
19 N82924e69317546959492f4a5b42e0f57
20 sg:journal.1087175
21 schema:name Acute Heart Failure—Basic Pathomechanism and New Drug Targets
22 schema:pagination 727-735
23 schema:productId N13fcfe3a240e4cdaba5897015adcdb8a
24 N3c1e41673f454eb8be6d8dc383279747
25 N7b657c62985f46cc8cd629ed2e876256
26 Na1aa725ac71043bba20eb1b388e728df
27 Nf2add1162446447985edea4c4fc56f27
28 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033395163
29 https://doi.org/10.1007/s00059-006-2911-x
30 schema:sdDatePublished 2019-04-10T13:05
31 schema:sdLicense https://scigraph.springernature.com/explorer/license/
32 schema:sdPublisher Nd754f2fe9e7c4c0d99362524d70a8063
33 schema:url http://link.springer.com/10.1007/s00059-006-2911-x
34 sgo:license sg:explorer/license/
35 sgo:sdDataset articles
36 rdf:type schema:ScholarlyArticle
37 N11316d5039a14717b09ab93acbd60a5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
38 schema:name Fatty Acids, Omega-3
39 rdf:type schema:DefinedTerm
40 N13fcfe3a240e4cdaba5897015adcdb8a schema:name readcube_id
41 schema:value 9f166e073751533280231557f922ce9d30cfa2a6e3f9543b9591856e18f776d9
42 rdf:type schema:PropertyValue
43 N3c11646b87c040189726559d34bf5ab3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
44 schema:name Cardiotonic Agents
45 rdf:type schema:DefinedTerm
46 N3c1e41673f454eb8be6d8dc383279747 schema:name nlm_unique_id
47 schema:value 7801231
48 rdf:type schema:PropertyValue
49 N43cce8e2643240e1ab45e2af64841e82 schema:volumeNumber 31
50 rdf:type schema:PublicationVolume
51 N6a14633b592248ccaac175a82a5a0a0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
52 schema:name Cardiac Output, Low
53 rdf:type schema:DefinedTerm
54 N7b657c62985f46cc8cd629ed2e876256 schema:name dimensions_id
55 schema:value pub.1033395163
56 rdf:type schema:PropertyValue
57 N80c0a91bd73f4a54ac5a2d941025379f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Acute Disease
59 rdf:type schema:DefinedTerm
60 N82924e69317546959492f4a5b42e0f57 schema:issueNumber 8
61 rdf:type schema:PublicationIssue
62 N82ce9d294e52428ba49314743e8952e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Clinical Trials as Topic
64 rdf:type schema:DefinedTerm
65 N8f7091f58f8f43b88eeb2ef2f5fcc848 rdf:first sg:person.01065373312.37
66 rdf:rest N9ea1b64f1c204e0685a7f5a30f7587b6
67 N916ba933e3854317a2a8c77d4a15f6f6 rdf:first sg:person.01177445163.00
68 rdf:rest Nd0503572e26649178d39b0cc3b2ff01a
69 N9ea1b64f1c204e0685a7f5a30f7587b6 rdf:first sg:person.0630132362.75
70 rdf:rest rdf:nil
71 Na1aa725ac71043bba20eb1b388e728df schema:name doi
72 schema:value 10.1007/s00059-006-2911-x
73 rdf:type schema:PropertyValue
74 Nbfd218989e04444e87682288581bb4c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Humans
76 rdf:type schema:DefinedTerm
77 Ncd12aef9c90549eda9e2047b339df5ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Drug Delivery Systems
79 rdf:type schema:DefinedTerm
80 Nd0503572e26649178d39b0cc3b2ff01a rdf:first sg:person.0611545536.24
81 rdf:rest N8f7091f58f8f43b88eeb2ef2f5fcc848
82 Nd754f2fe9e7c4c0d99362524d70a8063 schema:name Springer Nature - SN SciGraph project
83 rdf:type schema:Organization
84 Nf2add1162446447985edea4c4fc56f27 schema:name pubmed_id
85 schema:value 17149674
86 rdf:type schema:PropertyValue
87 Nfaecdf110e8944be80b1a312f486793b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Anti-Arrhythmia Agents
89 rdf:type schema:DefinedTerm
90 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
91 schema:name Medical and Health Sciences
92 rdf:type schema:DefinedTerm
93 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
94 schema:name Cardiorespiratory Medicine and Haematology
95 rdf:type schema:DefinedTerm
96 sg:journal.1087175 schema:issn 0340-9937
97 1615-6692
98 schema:name Herz
99 rdf:type schema:Periodical
100 sg:person.01065373312.37 schema:familyName Alter
101 schema:givenName Peter
102 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065373312.37
103 rdf:type schema:Person
104 sg:person.01177445163.00 schema:affiliation https://www.grid.ac/institutes/grid.10253.35
105 schema:familyName Rupp
106 schema:givenName Heinz
107 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177445163.00
108 rdf:type schema:Person
109 sg:person.0611545536.24 schema:familyName Rupp
110 schema:givenName Thomas P.
111 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611545536.24
112 rdf:type schema:Person
113 sg:person.0630132362.75 schema:affiliation https://www.grid.ac/institutes/grid.10253.35
114 schema:familyName Maisch
115 schema:givenName Bernhard
116 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630132362.75
117 rdf:type schema:Person
118 https://www.grid.ac/institutes/grid.10253.35 schema:alternateName Philipp University of Marburg
119 schema:name Department of Internal Medicine and Cardiology, Philipps University of Marburg, Marburg, Germany
120 Molecular Cardiology Laboratory, Department of Internal Medicine and Cardiology, Philipps University of Marburg, 35043, Marburg, Germany
121 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...